EAM Investors LLC Buys Shares of 69,096 Myriad Genetics, Inc. (MYGN)
EAM Investors LLC bought a new position in Myriad Genetics, Inc. (NASDAQ:MYGN) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 69,096 shares of the company’s stock, valued at approximately $3,178,000. EAM Investors LLC owned 0.09% of Myriad Genetics as of its most recent filing with the SEC.
Other institutional investors have also recently modified their holdings of the company. Royal Bank of Canada boosted its holdings in Myriad Genetics by 59.5% in the 1st quarter. Royal Bank of Canada now owns 4,597 shares of the company’s stock worth $136,000 after buying an additional 1,715 shares during the period. Robecosam AG boosted its holdings in Myriad Genetics by 39.8% in the 2nd quarter. Robecosam AG now owns 4,193 shares of the company’s stock worth $156,000 after buying an additional 1,193 shares during the period. First Quadrant L P CA bought a new position in Myriad Genetics in the 3rd quarter worth $201,000. Parametrica Management Ltd bought a new position in Myriad Genetics in the 3rd quarter worth $204,000. Finally, Commonwealth Equity Services LLC bought a new position in Myriad Genetics in the 2nd quarter worth $205,000. 98.21% of the stock is owned by institutional investors.
Several research analysts recently weighed in on MYGN shares. ValuEngine downgraded shares of Myriad Genetics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 12th. Zacks Investment Research raised shares of Myriad Genetics from a “hold” rating to a “buy” rating and set a $54.00 price objective for the company in a report on Friday, August 24th. BidaskClub downgraded shares of Myriad Genetics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 21st. TheStreet downgraded shares of Myriad Genetics from a “b” rating to a “c” rating in a report on Thursday, November 8th. Finally, Barclays increased their price objective on shares of Myriad Genetics from $35.00 to $38.00 and gave the company an “equal weight” rating in a report on Wednesday, August 22nd. Four equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $41.90.
Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings data on Tuesday, November 6th. The company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.30 by $0.13. Myriad Genetics had a net margin of 7.07% and a return on equity of 10.07%. The business had revenue of $202.30 million during the quarter, compared to the consensus estimate of $203.20 million. During the same quarter in the prior year, the firm earned $0.26 EPS. The business’s revenue was up 13.1% on a year-over-year basis. On average, sell-side analysts forecast that Myriad Genetics, Inc. will post 1.5 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This report was published by Daily Political and is owned by of Daily Political. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2018/11/20/eam-investors-llc-buys-shares-of-69096-myriad-genetics-inc-mygn.html.
About Myriad Genetics
Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.
Featured Article: What does cost of debt say about a company’s financial health?
Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGN).
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.